06/02/2016 02:30:00 1-888-992-3836 (toll free) Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

DateTimeSource
Headline
02/05/201612:47PMBWU.S. FDA Approves Expanded Use of Bristol-Myers Squibb’s Daklinza (daclatasvir) for Additional Challenging-to-treat Patient...
Updated label provides new treatment option for patients with HIV-1 coinfection, advanced cirrhosis, and post-liver transplant HCV recurrence Bristol-Myers Squibb Company (NYSE:BMY) announced today that Daklinza™ (daclatasvir, 60 mg), an NS5A replication complex inhibitor, has been approved by the U.S. Food and Drug... More...>>
02/03/201610:00AMBWBristol-Myers Squibb to Take Part in Leerink Swann Global Healthcare Conference
Bristol-Myers Squibb Company (NYSE:BMY) will take part in the Leerink Swann Global Healthcare Conference on Wednesday, February 10, 2016, in New York. Charles Bancroft, executive vice president and chief financial officer, will answer questions about the company at 1:25 p.m. EST. Investors and the general public are invited... More...>>
02/01/20169:00AMBWBristol-Myers Squibb Foundation Awards Eight Grants Totaling Nearly $11.5M to Make Lung & Skin Cancer Screening, Care More Ac...
Grants will support screening and navigation, and create new strategies and models for overcoming barriers to care for low-income and minority populations To mark National Cancer Prevention Month, the Bristol-Myers Squibb Foundation today announced eight grants totaling nearly $11.5 million that will help make lung and... More...>>
02/01/20166:55AMBWBristol-Myers Squibb & Pfizer Sign Collaboration with Portola Pharmaceuticals to Develop & Commercialize Investigational Ande...
Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer Inc. (NSYE:PFE) today announced that the companies have entered into a collaboration agreement with Portola Pharmaceuticals Inc. (Nasdaq: PTLA) to develop and commercialize the investigational agent andexanet alfa in Japan. Andexanet alfa, which is in Phase 3 clinical... More...>>
01/29/20167:48AMBWBristol-Myers Squibb & AbbVie Receive Positive CHMP Opinion for Investigational Antibody, Empliciti (elotuzumab), for the Tre...
Positive opinion based on reduction in the risk of disease progression or death with Empliciti in combination with standard of care regimen for multiple myeloma demonstrated in ELOQUENT-2 study Bristol-Myers Squibb Company (NYSE:BMY) and AbbVie (NYSE:ABBV) today announced that the Committee for Medicinal Products for Human... More...>>
01/28/20161:42PMDJNBristol-Myers Revenue Rises 1%, 2016 Profit Outlook Beats Expectations -- 2nd Update
By Tess Stynes Bristol-Myers Squibb Co. said its fourth-quarter revenue rose 1% amid continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy franchise and sales growth of other key drugs. Earnings, excluding certain one-time items, and revenue beat expectations. The company's 2016 per-share... More...>>
01/28/201612:41PMBWEuropean Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 & 4 Chronic Hepatitis C Patients with ...
Updated label provides additional treatment options for multiple HCV patient populations, including difficult-to-treat patients with decompensated cirrhosis HIV/HCV coinfected patients experience more rapid fibrosis progression than mono-infected HCV patients Bristol-Myers Squibb Company (NYSE:BMY) announced today that... More...>>
01/28/20168:08AMDJNBristol-Myers Revenue Rises 1%, 2016 Profit Outlook Beats Expectations -- Update
By Tess Stynes Bristol-Myers Squibb Co. said its fourth-quarter revenue rose 1% amid continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy franchise and sales growth of other key drugs. Earnings, excluding certain one-time items, and revenue beat expectations. The company's 2016 per-share... More...>>
01/28/20167:40AMDJNBristol-Myers Revenue Rises 1%
Bristol-Myers Squibb Co. said its fourth-quarter revenue rose 1% amid continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy franchise and sales growth of other key drugs. Earnings, excluding certain one-time items, and revenue beat expectations. The company's 2016 per-share earnings... More...>>
01/28/20167:29AMDJNBristol-Myers Revenue Rises 1%, 2016 Profit Outlook Beats Expectations
By Tess Stynes Bristol-Myers Squibb Co. said its fourth-quarter revenue rose 1% amid continued expansion of the pharmaceutical company's Opdivo cancer immunotherapy franchise and sales growth of other key drugs. Earnings, excluding certain one-time items, and revenue beat expectations. The company's 2016 per-share... More...>>
01/28/20166:59AMBWCheckMate -141, a Pivotal Phase 3 Opdivo (nivolumab) Head and Neck Cancer Trial, Stopped Early
Opdivo Study Demonstrates Superior Overall Survival Compared to Therapy of Investigator’s Choice in Patients with Recurrent or Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck Bristol-Myers Squibb Company (NYSE:BMY) today announced that a randomized Phase 3 study evaluating Opdivo (nivolumab... More...>>
01/28/20166:59AMBWBristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results
Increases Fourth Quarter Revenues 1% to $4.3 Billion, 4% for Full Year to $16.6 Billion Posts Fourth Quarter GAAP Loss Per Share of $0.08 and Non-GAAP EPS of $0.38 Achieves Significant Regulatory Milestones in Immuno-Oncology Opdivo Approved in the U.S. for Advanced Renal Cell Carcinoma and for First-Line Treatment of... More...>>
01/25/20166:59AMBWREPEAT/ Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresecta...
Opdivo + Yervoy Regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, based on accelerated approval1 Demonstrated significantly superior progression-free survival vs. Yervoy alone in CheckMate -067 with the first and only FDA-approved combination of immune checkpoint... More...>>
01/23/20166:36PMBWBristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen Receives Expanded FDA Approval in Unresectable or M...
Opdivo + Yervoy Regimen now indicated for unresectable or metastatic melanoma patients, regardless of BRAF mutational status, based on accelerated approval1 Demonstrated significantly superior progression-free survival vs. Yervoy alone in CheckMate -067 with the first and only FDA-approved combination of immune checkpoint... More...>>
01/20/20169:18AMDJNBristol-Myers Selects 3rd CytomX Cancer Therapy Candidate
By Tess Stynes Bristol-Myers Squibb Co. (BMY) expanded its collaboration effort with CytomX Therapeutics Inc. (CTMX) to a third experimental cancer treatment target, triggering a $10 million milestone payment for the California biopharmaceutical company. CytomX uses its Probody drug-development platform to develop immunotherapy... More...>>
01/17/20169:30PMDJNSamsung Gets European Approval for Enbrel Copy
SEOUL—Samsung Group said it has won approval from regulators to sell a near-replica of the blockbuster rheumatoid arthritis drug Enbrel in Europe, marking an early milestone for South Korea's biggest conglomerate in the nascent market for so-called biosimilar drugs. The approval comes as Samsung Bioepis Co... More...>>
01/08/20168:50AMDJNBristol-Myers Buys Rights to Dual Therapeutics Cancer Treatment
By Chelsey Dulaney Bristol-Myers Squibb Co. agreed to buy the global rights to Dual Therapeutics LLC's cancer treatment. Closely held Dual Therapeutics is developing a cancer therapeutic that more effectively targets cancer cells and spares normal cells. Bristol-Myers Squibb will pay an undisclosed upfront fee, plus... More...>>
01/05/201610:00AMBWBristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference
Bristol-Myers Squibb Company (NYSE: BMY) will present at the J.P. Morgan Healthcare Conference on Tuesday, January 12, 2016, in San Francisco. Giovanni Caforio, chief executive officer, will make a formal presentation about the company at 9:30 a.m. PST (12:30 p.m. EST). Investors and the general public are invited to listen... More...>>
12/23/20158:00AMBWSeattle Genetics & Bristol-Myers Squibb Announce Initiation of Phase 1/2 Clinical Trial of ADCETRIS® (Brentuximab Vedotin) i...
-Second of Two Planned Trials Combining ADCETRIS and Opdivo Under Clinical Collaboration Agreement- Seattle Genetics, Inc. (Nasdaq:SGEN) and Bristol-Myers Squibb (NYSE:BMY) today announced that the companies have initiated a phase 1/2 clinical trial of ADCETRIS (brentuximab vedotin) in combination with Opdivo (nivolumab... More...>>
12/21/20153:02AMDJNGlaxo Sets Deal For Bristol's HIV Drugs
(FROM THE WALL STREET JOURNAL 12/21/15) By Denise Roland LONDON -- GlaxoSmithKline PLC has agreed to pay Bristol-Myers Squibb up to $1.5 billion to acquire the U.S. company's pipeline of HIV drugs, a move which will bolster one of the U.K. drugmakers' strongest-performing areas. Glaxo said it would pay Bristol... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:us D:20160206 07:30:02